Cowpox

Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA

Retrieved on: 
Monday, October 23, 2023
Other Defense, Infectious Diseases, Contracts, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Defense, European Economic Area, Vaccinia, Medication, SIGA Technologies, Cowpox, Health Emergency Preparedness and Response Authority, Mpox, Meridian Medical Technologies, European Medicines Agency, JPA, MHRA, European, HERA, Smallpox, Tecovirimat, EMA, Joint, Gross metropolitan product, Medicines and Healthcare products Regulatory Agency, Health technology, Patient, Vaccine, Nursing, Meridian, EEA, EU

Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).

Key Points: 
  • Meridian Medical Technologies, LLC (Meridian), a global health security leader in providing medical countermeasures, today announced a framework contract under the Joint Procurement Agreement (JPA) was signed between Meridian and the European Commission’s Directorates-General (DG) HERA (Health Emergency Preparedness and Response Authority).
  • As part of a promotional licensing agreement, Meridian is a global commercialization partner for SIGA Technologies, Inc. (NASDAQ: SIGA), which is the marketing authorization holder and manufacturer of Tecovirimat SIGA.
  • Under the JPA, 13 participating countries from the European Economic Area (EEA) (Contracting Parties) can now efficiently purchase Tecovirimat SIGA, which has been approved by the European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications.
  • This agreement will result in country-level procurement of oral Tecovirimat SIGA and serve as a template for future procurement opportunities.

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022

Retrieved on: 
Thursday, March 2, 2023
Vaccination, Safety, Smallpox, Democratic republic, Infection, European Medicines Agency, TPOXX, FDA, Operation Active Endeavour, Human services, Biomedical Advanced Research and Development Authority, Research, NIAID, Regulation of tobacco by the U.S. Food and Drug Administration, Vaccinia, IV, Organization, Conference, Administration, United, DRC, Risk, BARDA, COVID-19, Mpox, Development, United States Department of Defense, Medicines and Healthcare products Regulatory Agency, National Institute of Allergy and Infectious Diseases, U.S. Department of Defense Strategy for Operating in Cyberspace, Government, EMA, Food, MHRA, Cowpox, Milk Income Loss Contract Payments, Administration for Strategic Preparedness and Response, Cryptocurrency, Vaccine

NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2022.

Key Points: 
  • Key Business and Operational Activity for 2022:
    In 2022, SIGA received approximately $77 million of international orders for oral TPOXX (tecovirimat) from 13 customers, of which 12 were new customers in 2022.
  • In comparison, the Company had approximately $13 million of international sales in 2021 and approximately $3 million of international sales in 2020.
  • These were the first option exercises under the 19C Contract for IV TPOXX, which followed its May 2022 FDA approval.
  • Capital Management Activity for 2022:
    In May of 2022, SIGA declared and paid a special cash dividend of $0.45 per share.

2022 World Market for Vaccines: The Market is Valued at $202.6 Billion up from $34.1 Billion in 2017 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Vaccination, Vaccine, Diphtheria, Public health, Infection, Society, Population growth, Death, Disease, Cowpox, Haemophilus influenzae, Rubella, Quality of life, COVID-19, Smallpox, Human, Growth, WHO, Tetanus, Statistics, Forecasting, Whooping cough, Vaccine-preventable diseases, Pharmaceutical industry

However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.

Key Points: 
  • However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.
  • The report contains market forecasts, company market share and expert market estimates for vaccine categories.
  • The report also looks at trends in the market for human vaccines used to prevent various types of disease.
  • It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period.

SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, October 27, 2022
Office of Inspector General, U.S. Department of Health and Human Services, Smallpox, Development, NASDAQ, Private Securities Litigation Reform Act, Assistant, Vaccinia, Unitary state, U.S. Securities and Exchange Commission, European Medicines Agency, BARDA, MHRA, FDA, Medication, Webcast, Department, Xi, Biomedical Advanced Research and Development Authority, Research, COVID, U.S. Department of Commerce Office of Security, Investor relations, EMA, Human, Company, Patent, Form, Conference, Cowpox, Annual report, Phrase, GLOBE, Vii, Medicines and Healthcare products Regulatory Agency, Monkeypox, Documentation, SEC, Security (finance), Strategy, Department of Defence, Risk, Vaccine, Policy, Contract, Ix, IV, COVID-19, Infection, United Kingdom, Government, Vaccination, Project Bioshield Act, Human services, Exercise, SIGA Technologies

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, November 3rd, 2022.

Key Points: 
  • NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, November 3rd, 2022.
  • Participating on the call will be Dr.Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.
  • Participants may access the call by dialing 1-844-826-3033 for domestic callers or 1-412-317-5185 for international callers.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.

SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, July 28, 2022
Contract, BARDA, Ix, Smallpox, Travel, Monkeypox, Policy, Company, Biomedical Advanced Research and Development Authority, Cowpox, Infection, Investor relations, Human, Research, EMA, Project Bioshield Act, Vii, U.S. Department of Commerce Office of Security, Virus, Vaccinia, GLOBE, Documentation, Monkeypox virus, Phrase, Patent, COVID-19, Conference, Webcast, Exercise, Human services, European Medicines Agency, Disease, FDA, Annual report, Risk, Vaccine, IV, Xi, Forward-looking statement, Development, Private Securities Litigation Reform Act, Office of Inspector General, U.S. Department of Health and Human Services, SIGA Technologies, NASDAQ, Assistant, Vaccination, Animal

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, August 4th, 2022.

Key Points: 
  • NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at4:30 P.M. ETonThursday, August 4th, 2022.
  • Participating on the call will be Dr.Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dennis Hruby, Chief Scientific Officer.
  • SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.
  • Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness.

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

Retrieved on: 
Friday, July 15, 2022
U.S. Securities and Exchange Commission, Tumor microenvironment, Infection, Therapy, Risk, Project Bioshield Act, Smallpox, EMA, SIGA Technologies, Vaccine, Government, Ix, Office of Inspector General, U.S. Department of Health and Human Services, Research, CEO, Regulation of tobacco by the U.S. Food and Drug Administration, Xi, European Medicines Agency, Food, Private Securities Litigation Reform Act, Forward-looking statement, Vaccinia, Assistant, Policy, Exercise, NASDAQ, Biomedical Advanced Research and Development Authority, Vaccination, Physician, U.S. Department of Commerce Office of Security, Cowpox, Patient, Phrase, COVID-19, Partnership, Contract, Patent, Cancer, Human services, Monkeypox, GLOBE, Documentation, Development, IV, Annual report, FDA, Virus, Vii, BARDA, Pharmaceutical industry, NEJM

NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX (tecovirimat) available for use with KaliVirs proprietary oncolytic vaccinia immunotherapy platform.

Key Points: 
  • NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX (tecovirimat) available for use with KaliVirs proprietary oncolytic vaccinia immunotherapy platform.
  • KaliVir is an innovator in the creation of oncolytic viral immunotherapies, and we are excited to enter into this collaboration with them, said Dr. Phil Gomez, CEO of SIGA.
  • This collaboration helps bring new levels of assurance to physicians, regulators, and especially patients receiving these promising investigational therapies.
  • We are pleased to announce this collaboration with SIGA Technologies, said Helena Chaye, Ph.D., J.D., CEO of KaliVir.

SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Retrieved on: 
Tuesday, July 12, 2022
Annual report, Development, Smallpox, US Foods, Office of Inspector General, U.S. Department of Health and Human Services, Xi, Biomedical Advanced Research and Development Authority, Patient, Policy, Private Securities Litigation Reform Act, Human, PHAC, Infection, Cowpox, IV, EMA, CEO, BARDA, GLOBE, Patent, National security, Public Health Agency, DND, Virus, Risk, Forward-looking statement, Ix, Public Health Agency of Canada, Exercise, Vaccination, Contract, Monkeypox, Vii, Orthopoxvirus, COVID-19, European Medicines Agency, Phrase, FDA, SIGA Technologies, NASDAQ, Vaccinia, Vaccine, Health Canada, Human services, Documentation, Government, Project Bioshield Act, Assistant, U.S. Department of Defense Strategy for Operating in Cyberspace, Research

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX® (tecovirimat), including approximately $2 million for initial procurement by two new international jurisdictions and approximately $26 million for procurement by Canada, of which approximately $22 million is being procured by the Public Health Agency of Canada (PHAC) and approximately $4 million is being procured by the Canadian Department of National Defence (DND) under existing contracts. One of the new jurisdictions is in Europe, and the other new jurisdiction is in the Asia Pacific region.  

Key Points: 
  • NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced approximately $28 million of procurement orders for oral TPOXX (tecovirimat), including approximately $2 million for initial procurement by two new international jurisdictions and approximately $26 million for procurement by Canada, of which approximately $22 million is being procured by the Public Health Agency of Canada (PHAC) and approximately $4 million is being procured by the Canadian Department of National Defence (DND) under existing contracts.
  • In combination with the approximately $13 million PHAC order that was previously disclosed on the last investor call, PHAC and DND have ordered approximately $39 million of oral TPOXX (tecovirimat) this year.
  • To date this year, SIGA has received approximately $56 million of international orders for oral TPOXX (tecovirimat) from six jurisdictions, of which five are new customers.
  • The increase over the last two months in international orders of oral TPOXX (tecovirimat) reflects an initial public health reaction to the evolving monkeypox outbreak, said Phil Gomez, CEO of SIGA.

SIGA Technologies Receives Approval from UK for Tecovirimat

Retrieved on: 
Friday, July 8, 2022
European Medicines Agency, Research, GLOBE, Ix, COVID-19, Smallpox, EMA, Contract, Food, Biomedical Advanced Research and Development Authority, Monkeypox, Human services, BARDA, Vaccine, Patent, Vaccination, Regulation of tobacco by the U.S. Food and Drug Administration, Cowpox, FDA, Government, Exercise, Phrase, Xi, Development, Infection, Risk, Vii, Forward-looking statement, Documentation, CEO, Human, SIGA Technologies, Policy, Private Securities Litigation Reform Act, NASDAQ, Annual report, Assistant, Project Bioshield Act, United States Department of Health and Human Services, Health Canada, United Kingdom, Vaccinia, IV, Pharmaceutical industry

In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.

Key Points: 
  • In early 2022 SIGA also received market authorization for tecovirimat from the European Medicines Agency for the treatment of smallpox, monkeypox, cowpox, and complications from vaccinia infection.
  • SIGA Technologies, Inc.is a commercial-stage pharmaceutical company focused on the health security market.
  • Oral tecovirimat received approval from theEuropean Medicines Agency(EMA) in 2022.
  • The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox.

SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)

Retrieved on: 
Thursday, June 23, 2022
Biomedical Advanced Research and Development Authority, Government, European Medicines Agency, Office of Inspector General, U.S. Department of Health and Human Services, Leadership, Forward-looking statement, Infection, Smallpox, Vii, Exercise, Monkeypox, SIGA Technologies, Documentation, Orthopoxvirus, Human services, GLOBE, Patent, Annual report, U.S. Department of Defense Strategy for Operating in Cyberspace, Phrase, CEO, Cowpox, Private Securities Litigation Reform Act, Vaccination, Policy, NASDAQ, Project Bioshield Act, Contract, Public health, FDA, COVID-19, BARDA, IV, Health Canada, LLC, Virus, Patient, Xi, Risk, US Foods, Vaccine, Human, Research, Meridian Medical Technologies Inc., Ix, Development, Vaccinia, EMA, Assistant, Military personnel, Pharmaceutical industry, Meridian

Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.

Key Points: 
  • Procurement orders from new international jurisdictions have occurred as SIGA has received a large and ongoing number of inquiries about accessing oral TPOXX, highlighting the importance of health security preparedness, said Phil Gomez, CEO of SIGA.
  • The orders from the new international jurisdictions represent the first procurements of oral TPOXX (tecovirimat) directly in response to the evolving global monkeypox outbreak.
  • SIGA currently expects to deliver approximately $4 million of oral TPOXX (tecovirimat) under the two new contracts within the next 45 days.
  • With respect to the order from an existing customer, SIGA recently fulfilled the order by delivering $2 million of oral TPOXX (tecovirimat).

Gold Standard Diagnostics, a Eurofins Technologies Company, Announces a PCR Assay for the Detection of the Monkeypox and Orthopox Virus

Retrieved on: 
Thursday, June 23, 2022
Research, Medical Supplies, Infectious Diseases, Genetics, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Laboratory, Monkeypox virus, View, Cowpox, Centers for Disease Control and Prevention, GSD, Research, Smallpox, Infection, Monkeypox, Severe acute respiratory syndrome coronavirus 2, ELISA, Life, Food, Patient, Eurofins Scientific, CDC, PCR, Center, Vaccine, Orthopoxvirus

Gold Standard Diagnostics Europe continues its response to the threat of emerging infectious diseases by developing a new multiplex Real-time PCR assay for the detection of the monkeypox virus and its differentiation from other orthopox viruses.

Key Points: 
  • Gold Standard Diagnostics Europe continues its response to the threat of emerging infectious diseases by developing a new multiplex Real-time PCR assay for the detection of the monkeypox virus and its differentiation from other orthopox viruses.
  • The monkeypox virus has raised significant concerns given its recent spread, with more than 2500 confirmed cases in 37 countries [1].
  • The Centers for Disease Control and Prevention (CDC) has issued an alert level 2 for the monkeypox virus.
  • The Mplex Monkeypox, Orthopox Real-time PCR assay uses a generic target for orthopox viruses and a specific target for monkeypox and will be available for research use only from the beginning of July.